- Home
- MKL vs VTRS Comparison
MKL vs VTRS Comparison
Compare MKL & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKL | VTRS |
|---|---|---|
| Founded | 1930 | 1961 |
| Country | United States | United States |
| Employees | N/A | 30000 |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2B | 21.0B |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MKL | VTRS |
|---|---|---|
| Price | $1,942.36 | $19.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 12 |
| Target Price | ★ $1,966.83 | $20.00 |
| AVG Volume (30 Days) | 60.7K | ★ 8.5M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 91.90 | N/A |
| Revenue | ★ $15,513,233,000.00 | $14,299,900,000.00 |
| Revenue This Year | N/A | $3.35 |
| Revenue Next Year | $0.35 | $2.99 |
| P/E Ratio | ★ $21.27 | $384.40 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1,704.17 | $9.99 |
| 52 Week High | $2,207.59 | $19.51 |
Technical Indicators
Market Signals| Indicator | MKL | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 68.21 | 66.26 |
| Support Level | $1,918.84 | $15.94 |
| Resistance Level | $2,013.77 | N/A |
| Average True Range (ATR) | 36.53 | 0.52 |
| MACD | 7.85 | 0.05 |
| Stochastic Oscillator | 64.36 | 85.95 |
Price Performance
Historical ComparisonAbout MKL Markel Group Inc.
Markel's primary business is property-casualty insurance. The company focuses primarily on specialty lines, ranging from areas such as executive liability to commercial equine insurance. The company uses capital generated by its insurance operations to buy noninsurance operations in diverse areas, such as bakery equipment manufacturing and residential homebuilding.
About VTRS Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.